1. Home
  2. MTZ vs VTRS Comparison

MTZ vs VTRS Comparison

Compare MTZ & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MasTec Inc.

MTZ

MasTec Inc.

HOLD

Current Price

$215.23

Market Cap

19.0B

Sector

Industrials

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$17.08

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTZ
VTRS
Founded
1929
1961
Country
United States
United States
Employees
N/A
30000
Industry
Water Sewer Pipeline Comm & Power Line Construction
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0B
18.7B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
MTZ
VTRS
Price
$215.23
$17.08
Analyst Decision
Strong Buy
Buy
Analyst Count
18
4
Target Price
$339.47
$13.50
AVG Volume (30 Days)
1.4M
6.6M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
3.21%
EPS Growth
146.12
N/A
EPS
2.42
0.05
Revenue
$14,299,171,000.00
$14,299,900,000.00
Revenue This Year
$20.38
$4.41
Revenue Next Year
$10.18
$1.96
P/E Ratio
$91.61
$343.60
Revenue Growth
16.22
N/A
52 Week Low
$182.34
$9.43
52 Week High
$441.43
$18.39

Technical Indicators

Market Signals
Indicator
MTZ
VTRS
Relative Strength Index (RSI) 39.86 60.46
Support Level $209.67 $16.02
Resistance Level $232.42 $18.23
Average True Range (ATR) 10.64 0.34
MACD 1.62 0.07
Stochastic Oscillator 39.55 91.25

Price Performance

Historical Comparison
MTZ
VTRS

About MTZ MasTec Inc.

MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: